What Mylan’s CEO learned from the EpiPen outrage

Published



SAN FRANCISCO – Mylan CEO Heather Bresch reflected Wednesday on what she learned from months of public outrage over her company’s dramatic price increase for the EpiPen allergy shot.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.